Cambridge Laboratories Limited Appoints Peter Butterfield as UK Commercial Manager

13 September 2007 – Cambridge Laboratories (“Cambridge” or the “Company”), the privately owned specialty pharmaceutical company, today announces the appointment of Peter Butterfield as UK Commercial Manager. Peter, aged 31, becomes a member of the senior management team at Cambridge. He joined Cambridge in 2004 and will now be responsible for all UK sales and marketing activities including managing a team of Business Unit Managers within the Company’s UK subsidiary.

Prior to joining Cambridge in 2004, he spent six years at SmithKline Beecham (subsequently GlaxoSmithKline Plc, NYSE: GSK) where he acquired extensive sales and marketing knowledge, latterly responsible for market development of the UK respiratory franchise. Peter holds an honours degree in Pharmacology from the University of Edinburgh.

Enquiries: Cambridge Laboratories Mark Evans, CEO Tel: +44 191 296 9369 David Wildy, CFO Tel: +353 1 631 9352

Financial Dynamics Deborah Scott/Emma Thompson Tel: +44 20 7831 3113

About Cambridge Laboratories Cambridge is a fast growing, dynamic and entrepreneurial pharmaceutical company with extensive product development and commercialisation expertise focussed on innovative products for diseases of the central nervous system. Cambridge has an exciting portfolio of products, both on the market and in development, derived from its proprietary discovery efforts and a carefully constructed network of international partnerships for research, development, sourcing and global commercialisation. Utilising this unusual business model, Cambridge is dedicated to delivering significant value to patients, physicians and partners around the world. For further information please visit our website www.camb-labs.com

In February 2007, a Complete Response was submitted to the FDA in respect of an application for marketing approval for XENAZINE® in the US for the treatment of chorea associated with Huntington’s disease.

In February 2006, Cambridge reported results of a Phase III trial, published in Neurology, demonstrating that tetrabenazine significantly reduced patients’ chorea burden without causing many of the side effects seen with other treatments. The 84 patient study was the largest Phase III study ever undertaken in Huntington’s chorea.

Back to news